Associate 
Colin has over 30 years of pharmaceutical research and development, 28 of them regulatory affairs. His specialty is regulatory affairs of emerging markets for which he is a recognised industry leader. He has extensive knowledge and experience of working in Asia, Middle East, Africa, Latin America, and Europe and he has been head of emerging markets in global regulatory affairs, for The Wellcome Foundation, GlaxoWellcome, Pfizer and Eisai. He has provided independent regulatory intelligence and advice to companies on accessing new counties, new product regulatory strategy, and product maintenance activities. He has delivered many robust product developments, filing and approval strategies for company pipeline, established and in licensed, products. Innovative regulatory strategies have often been developed to produce industry-leading application approval speeds.
For the European Federation of Pharmaceutical Industries and Associations, he has been chair of the International Regulatory Affairs ad hoc group, chair of the Asia Regulatory Conference Organising Committee, a member of the Regulatory Policy and Technical Standards Committee and a member of the China Network. He is also a member of The Pharmaceutical Research and Manufacturers of America (China).
